Scarica l'app Stockscreener
30.13
1.14%
0.34
Pre-mercato:
29.79
-0.34
-1.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TEVA Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Teva Pharmaceutical Industries Ltd Adr Borsa (TEVA) Ultime notizie
Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead? - The Motley Fool
Teva Pharma stock hits 52-week high at 29.81 USD By Investing.com - Investing.com Nigeria
Teva Pharma stock hits 52-week high at 29.81 USD - Investing.com
TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia - Finviz
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play - Finviz
30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks - Finviz
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December - Sahm
Is the Market Bullish or Bearish on Teva Pharmaceutical Industries Ltd? - Sahm
Teva stock hits 52-week high at 26.38 USD - Investing.com
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva® - Sahm
Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma's Biggest Challenges - Finviz
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Shares: Cheap or Risky? - fostersleader.com
ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell? - Finviz
Teva Pharma stock hits 52-week high at $25.96 By Investing.com - Investing.com Nigeria
Teva Pharma stock hits 52-week high at $25.96 - Investing.com
Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year? - sharewise.com
Why Teva Pharmaceutical Stock Rocked the Market Today - Finviz
Teva Fires on All Cylinders as Innovation and Pipeline Support Growth and Cost-Controls Lift Margins - Morningstar
Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook - Sahm
Earnings call transcript: Teva beats Q3 2025 forecasts, stock surges - Investing.com
Teva stock hits 52-week high at 23.07 USD - Investing.com
Teva stock hits 52-week high at 23.07 USD By Investing.com - Investing.com Philippines
Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November - Sahm
Earnings call transcript: Teva’s Q2 2025 shows steady growth, stock rises - Investing.com
Teva Pharmaceutical Industries Ltd (TEVA) Stock Price, Trades & News - GuruFocus
eBay Upgraded, Meta Platforms Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
ETFs Investing in Teva Pharmaceutical Industries Limited Sponsored ADR Stocks - TradingView
TEVA Stock Price and Chart — VIE:TEVA - TradingView
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe - Sahm
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures - Sahm
Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2026 - Finviz
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder - Sahm
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Sahm
SciSparc And AutoMax Call Off Merger - Sahm
AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction - Ariva
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed - Ariva
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting - Sahm
Bayforest Capital Ltd Sells 3,875 Shares of Teva Pharmaceutical Industries Ltd. $TEVA - Defense World
Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy - Ariva
Teva Pharmaceutical ADR Trying To Close In On Key Technical Measure - inkl
Teva stock rises on launch of first generic weight loss GLP-1 drug - Investing.com Nigeria
Teva Shares Rise Following Launch of First Generic GLP-1 Weight Loss Drug - MSN
Teva stock rises on launch of first generic weight loss GLP-1 drug By Investing.com - Investing.com South Africa
3.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):